drugset / Trial / NCT05276804
The POUR (Postoperative Urinary Retention) Study
Phase 3
Completed
171 enrolled
Wake Forest University Health Sciences
Merck Sharp & Dohme LLC · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary aim of this study will be to compare the rate of postoperative urinary retention between patients receiving Sugammadex and those receiving traditional reversal agents
Timeline
- Start
- 2022-04-13
- Primary completion
- 2024-09-03
- Completion
- 2024-09-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sugammadex | Other / unclassified | 2 mg/kg | — |
| Subject | Sugammadex | Other / unclassified | 4 mg/kg | — |